Background: The blockade of immune regulatory sites, CTLA-4, PD-1, and PD-L1 with Immune Checkpoint Inhibitors has revolutionized...

Abstract Background and objectives: Immune checkpoint inhibitor (ICI) use is increasing in the United States, real world data on acute...